As part of its review of UK medicines legislation, the MHRA has been looking at the provisions which relate to the product licences of right (PLR) regime and homeopathy.  The main organisations and representative bodies have already been contacted informally and asked to comment on the initial thinking in this area; the MHRA is now consulting more widely seeking views about the likely regulatory impact and any implications not so far identified.  Please see the link below for details (consultation closes on 18 February 2011).